Novavax, Inc.

NVAX

US6700024010

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 13/06/2025 BST			5-day change	1st Jan Change
6.940 ^USD	-2.94%		-6.85%	-13.68%

06-13	Moderna falls on doubts over new CDC panel's backing of RSV vaccine	RE
06-12	Novavax: positive results for Covid/flu vaccine	CF

Novavax Stock Price More Than Doubles After COVID-19 Vaccine Licensing Deal With Sanofi

Published on 10/05/2024 at 16:25, updated on 10/05/2024 at 16:26

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Novavax, Inc.

Moderna falls on doubts over new CDC panel's backing of RSV vaccine	06-13	RE
Novavax: positive results for Covid/flu vaccine	06-12	CF
Kennedy replaces fired US CDC panel members, includes anti-vaccine proponents	06-12	RE
Kennedy replaces fired US CDC panel members, includes anti-vaccine proponents	06-11	RE
Novavax, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-11-2025 02:00 PM	06-11
Global markets live: Tesla, Nvidia, Boeing, Mistral, Nintendo…	06-11
Sector Update: Health Care Stocks Higher Pre-Bell Wednesday	06-11	MT
Novavax's COVID-flu combo vaccine shows strong immune response in trial	06-11	RE
Novavax's COVID-flu combo vaccine shows strong immune response in trial	06-11	RE
Novavax's Covid-19-Influenza Combination and Stand-Alone Influenza Vaccine Candidates Showed Robust Immune Responses and Were Well Tolerated in Initial Cohort of A Phase 3 Trial	06-11	CI
Novavax's Covid-Influenza Combo, Standalone Flu Vaccines Show 'Robust Immune Responses' in Phase 3 Study	06-11	MT
Novavax's COVID-flu combo and standalone flu shots improve immunity in late-stage study	06-11	RE
Novavax's Combo & Flu Vaccines Show Strong Immune Response, Tolerated Well in Phase 3 Trial	06-11	RE
Vaccine stocks muted as investors assess Kennedy's overhaul of key panel	06-10	RE
Vaccine stocks muted as investors assess Kennedy's overhaul of key panel	06-10	RE
Novavax, Inc., Q1 2025 Earnings Call, May 08, 2025	06-06
US CDC keeps COVID vaccine option for healthy children	05-31	RE
US CDC keeps COVID vaccine option for healthy children	05-31	RE
Novavax Inc - Eliminates COO Position, Terminates John Trizzino - SEC Filing	05-27	RE
CDC Removes Healthy Children, Pregnant Women From COVID Vaccine Schedule	05-27	MT
Moderna files for review of updated COVID vaccine	05-23	RE
Moderna files for review of updated COVID vaccine	05-23	RE
COVID shots should target newer strains of JN.1 variant, US FDA advisers say	05-22	RE
COVID shots should target newer strains of JN.1 variant in 2025-26 campaign, US FDA advisers say	05-22	RE
US FDA advisers to weigh composition of COVID vaccines for 2025-2026	05-22	RE

Novavax, Inc. is a biotechnology company, which discovers, develops and commercializes vaccines to prevent serious infectious diseases. The Company offers a differentiated vaccine platform that combines a recombinant protein approach, advanced nanoparticle technology and its patented Matrix-M adjuvant to enhance the immune response. It has one commercial program, for vaccines to prevent COVID-19, which includes Nuvaxovid prototype COVID-19 vaccine (NVX-CoV2373 or prototype vaccine) and Nuvaxovid updated COVID-19 vaccine (NVX-CoV2601 or updated vaccine) (collectively, COVID-19 Vaccine). The Company is advancing the development of other vaccine candidates, including its COVID19-Influenza Combination (CIC) vaccine candidate and additional vaccine candidates. Its COVID-19 Vaccine and its other vaccine candidates incorporate the Companyâs proprietary Matrix-M adjuvant to enhance the immune response and stimulate higher levels of functional antibodies and induce a cellular immune response.

Employees

952

Sector

Biotechnology & Medical Research

Calendar

06-20 - Annual General Meeting

More about the company